HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...

Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer As of June 28, 2024, 3,782 ...

AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

The report suggested that Aduhelm was more of an outlier, as investigators found only three troubling instances out of a sample of 24 accelerated approval drugs. But Ivan Troy, social science ...

A new study suggests clinical utility of the first FDA-approved genetic test to help gauge an individual’s risk for opioid ...

Aguilar, who used to work as a medical representative for the U.S. pharmaceutical ... submitting the soil sample responsible for the development of Ilotycin (Eryhromycin, Lilly)," Blair wrote ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) ...

The sample of Wall Street analysts covering ... which is the U.S. pharmaceutical giant Eli Lilly (LLY). LLY's Zepbound poses a significant threat to NVO's Wegovy. Fierce competition with a ...

Updated 2025 market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!